Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Becton Dickinson is a global medical technology company with three core segments: BD Medical (medication management, infusion systems, diabetes care devices), BD Life Sciences (specimen collection, diagnostics, biosciences research tools), and BD Interventional (surgery, peripheral intervention, urology). The company operates manufacturing across 50+ countries with significant exposure to hospital capital equipment cycles, procedural volumes, and diabetes device innovation competing against Medtronic, Abbott, and Danaher.
BD generates revenue through a razor-razorblade model in many product lines: selling capital equipment (infusion pumps, diagnostic instruments, surgical tools) followed by high-margin recurring consumables (needles, syringes, test tubes, reagents). The company benefits from hospital formulary lock-in once systems are installed, creating sticky customer relationships. Pricing power derives from FDA regulatory barriers, extensive distribution networks in 190+ countries, and integrated solutions that reduce hospital workflow complexity. Gross margins of 45.4% reflect mix of lower-margin commodity products (basic syringes) and higher-margin specialty devices (safety-engineered needles, advanced diagnostics).
Hospital procedure volumes and elective surgery trends - drives consumables demand across all three segments
Diabetes device market share gains/losses versus Novo Nordisk pen needles and continuous glucose monitoring competitors
Capital equipment order rates from hospitals - leading indicator for future consumables pull-through
Pricing dynamics in commodity products (basic syringes, needles) facing generic competition and GPO pressure
M&A integration execution - BD acquired C.R. Bard for $24B in 2017, integration savings impact margins
FDA approvals for new product launches in high-growth categories (robotic surgery, interventional oncology)
Shift toward value-based care and bundled payments pressures hospital margins, forcing aggressive cost reduction on medical device purchases and favoring lower-cost alternatives
GLP-1 diabetes drugs (Ozempic, Wegovy) reducing insulin-dependent diabetes population over time, threatening BD's diabetes care device franchise
Increasing regulatory scrutiny on device safety (needle-stick injuries, infusion pump malfunctions) requiring costly recalls and design modifications
Abbott and Dexcom dominating continuous glucose monitoring market while BD remains focused on traditional insulin delivery, risking obsolescence in diabetes care
Chinese medical device manufacturers (Mindray, Lepu Medical) gaining share in emerging markets with 40-50% lower pricing on commodity products
Medtronic and Intuitive Surgical advancing robotic surgery platforms that could displace BD's traditional surgical instrument portfolio
Debt/Equity of 0.53x is manageable but limits M&A flexibility for transformative acquisitions needed to enter high-growth categories like robotics or digital health
Pension obligations and retiree healthcare liabilities from legacy manufacturing workforce create off-balance-sheet drag on cash flow
moderate - Hospital procedure volumes correlate with employment levels (insured population) and consumer confidence in seeking elective procedures. Recession reduces elective surgeries (interventional segment) but core diabetes and diagnostic testing remain resilient. International sales (~60% of revenue) expose BD to global GDP growth, particularly in emerging markets where healthcare infrastructure investment is GDP-sensitive.
Rising rates have dual impact: (1) Negative for hospital capital equipment budgets as healthcare systems face higher financing costs for large purchases, delaying instrument replacements; (2) Negative for BD's valuation multiple as medical device stocks trade on forward P/E compression when risk-free rates rise, reducing appeal of 15-20x earnings multiples. However, BD's $11B debt load benefits from fixed-rate structure, limiting direct interest expense impact. Moderate sensitivity overall.
Minimal direct credit exposure. BD sells primarily to hospitals, government health systems, and large distributors with strong credit profiles. Days sales outstanding around 60 days reflects stable collections. However, hospital financial stress during credit tightening can delay capital equipment purchases and pressure pricing on consumables through GPO negotiations.
value - BD trades at 15.9x EV/EBITDA, below historical 18-20x range, attracting value investors betting on margin expansion from Bard synergies and procedure volume recovery post-pandemic. Recent 47% 3-month rally suggests momentum investors entering on earnings beats. Dividend yield around 1.3% provides modest income component but not primary attraction. Quality-focused investors appreciate durable competitive moats in hospital formularies and regulatory barriers.
moderate - Beta typically 0.8-0.9 reflecting defensive healthcare characteristics but with cyclical exposure to elective procedures. Recent 47% 3-month surge indicates elevated volatility around earnings catalysts and macro sentiment shifts on healthcare spending. Less volatile than biotech but more volatile than pharma due to capital equipment sensitivity.
